These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24678765)

  • 1. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Singh JA
    Arthritis Res Ther; 2014 Mar; 16(2):R82. PubMed ID: 24678765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol.
    Singh JA
    Trials; 2021 Dec; 22(1):879. PubMed ID: 34863255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
    Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
    Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
    Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    Wells AF; MacDonald PA; Chefo S; Jackson RL
    BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives.
    Singh JA; Herbey I; Bharat A; Dinnella JE; Pullman-Mooar S; Eisen S; Ivankova N
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1724-1732. PubMed ID: 28118526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
    van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
    PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.